Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. (Q33928609)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. |
scientific article |
Statements
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 (English)
B Coudert
J Cadranel
E Quoix
V Westeel
E Dansin
J Madelaine
A Madroszyk
S Friard
C Daniel
F Morin
ERMETIC Collaborative Group